AC Immune director granted shares, options

AC Immune SA director Renee Aguiar-Lucander reported equity compensation awards rather than open-market trades.

Rhea-AI Filing Summary

AC Immune SA director Renee Aguiar-Lucander reported equity compensation awards rather than open-market trades. On June 11, 2026, she received a restricted share unit grant covering 16,568 common shares under the AC Immune SA 2016 Stock Option and Incentive Plan.

Following this grant, 51,136 common shares are underlying her outstanding restricted share units. She was also awarded options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036.

Insider Trade Summary

Grant/Award: 55,457 shares

Grant/Award 2 txns

Insider AGUIAR-LUCANDER RENEE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	38,889	$0.00	$0.00
Grant/Award	Common Share	16,568	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 38,889 contracts (Direct); Common Share — 51,136 shares (Direct)

Footnotes (3)

1. F1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).
2. F2. Comprised of 51,136 common shares underlying outstanding restricted share units.
3. F3. On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027.

Key Figures

RSU grant size: 16,568 units RSUs outstanding: 51,136 shares Option grant size: 38,889 options +4 more

7 metrics

RSU grant size 16,568 units Restricted share units granted on June 11, 2026 under 2016 SOIP

RSUs outstanding 51,136 shares Common shares underlying outstanding restricted share units after grant

Option grant size 38,889 options Share options granted on June 11, 2026 under SOIP

Option exercise price $2.62 per share Exercise price for 38,889 share options

Option vesting date June 10, 2027 Date when the granted share options fully vest

Option expiration date June 10, 2036 Scheduled expiration of the granted share options

Common shares following 51,136 shares Total common shares reported following RSU transaction

Key Terms

restricted share unit, Stock Option and Incentive Plan, share options, exercise price, +1 more

5 terms

restricted share unit financial

"received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

Stock Option and Incentive Plan financial

"under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP)"

share options financial

"received share options with respect to 38,889 shares under the SOIP"

Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.

exercise price financial

"share options with respect to 38,889 shares under the SOIP ... exercise price of $2.62 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The share options will fully vest on June 10, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AC Immune (ACIU) director Renee Aguiar-Lucander report in this Form 4 filing?

She reported receiving equity compensation awards, not market trades. On June 11, 2026, she was granted 16,568 restricted share units and options for 38,889 common shares under AC Immune’s 2016 Stock Option and Incentive Plan.

How many AC Immune shares does Renee Aguiar-Lucander hold through restricted share units after this grant?

After the June 11, 2026 grant, she has 51,136 common shares underlying outstanding restricted share units. This figure reflects her RSU-based exposure reported in the filing, rather than open-market share purchases or sales.

What are the key terms of the share options granted to Renee Aguiar-Lucander by AC Immune (ACIU)?

She received options on 38,889 common shares with a $2.62 exercise price. These options were granted on June 11, 2026, will fully vest on June 10, 2027, and are scheduled to expire on June 10, 2036 if not exercised.

Does this AC Immune Form 4 show Renee Aguiar-Lucander buying or selling shares on the open market?

No, the filing shows compensation-related acquisitions only. The transactions are coded as awards of restricted share units and stock options, with no reported open-market purchases or sales of AC Immune common shares.

Under which plan were Renee Aguiar-Lucander’s AC Immune equity awards granted?

Both the 16,568 restricted share units and the 38,889 share options were granted under the AC Immune SA 2016 Stock Option and Incentive Plan, the company’s equity incentive program used for awarding stock-based compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 06:59 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AGUIAR-LUCANDER RENEE

(Last) (First) (Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE 1015

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Share	06/11/2026		A		16,568	A	$0(1)	51,136(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.62	06/11/2026		A		38,889		06/10/2027(3)	06/10/2036	Common Share	38,889	$0	38,889	D

Explanation of Responses:

1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).

2. Comprised of 51,136 common shares underlying outstanding restricted share units.

3. On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027.

	Matthias Maurer as Attorney-in-Fact for Renee Aguiar-Lucander	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)